Key result
Once-daily orforglipron reduced HbA1c compared to placebo at 40 weeks in patients with early type 2 diabetes inadequately controlled with diet and exercise.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
CLINICAL IMPACT RATINGS: GIM/FP/GP: [Formula: see text] Endocrinology: [Formula: see text].
No takes yet. Share an insight, caveat, or question.
Shahid et al. (2025) studied this question. Once-daily orforglipron reduced HbA1c compared to placebo at 40 weeks in patients with early type 2 diabetes inadequately controlled with diet and exercise.
Synapse has enriched 10 related papers. Consider them for comparative context: